Basic Introduction:

Tibet Nuodikang Pharmaceutical Co., Ltd. was founded in the Tibet Autonomous Region on July 14, 1999, and its shares began to be traded on the Shanghai Stock Exchange on July 21, 1999. It is the first high-tech pharmaceutical listed enterprise in the Tibet Autonomous Region. The stock name is "Tibet Pharmaceutical Industry", and the stock code is 600211. Since its establishment, the company has been recognized as a national-level high-tech enterprise and a key leading enterprise in agricultural industrialization. The company's graphic trademark (auspicious cloud pattern) has been recognized as a well-known trademark in China by the State Administration for Industry and Commerce. The company has won many honors, including the First Prize of the Science and Technology Progress Award of the China Association of Traditional Chinese Medicine, the Reputation List of Chinese Listed Companies — the Most Growth-oriented Listed Company in the Biomedical Field, the Golden Bull Most Investment-worthy Award, and the First Prize of the Sichuan Provincial Science and Technology Progress Award.

Adhering to the concept of "Science Achieves Health, and Health Achieves the Future", after more than two decades of development, the company has grown into a modern pharmaceutical enterprise integrating research and development, production, and sales. The company has established an enterprise technology center; four pharmaceutical production bases for biological products, Tibetan medicine products, and traditional Chinese medicine products that meet GMP standards; one planting base for traditional Chinese and Tibetan medicinal materials that meets GAP standards; and one vaccine production base. Currently, the company has nine subsidiaries in Tibet, Sichuan, Shanghai, Hong Kong and other places, namely Sichuan Nuodikang Weiguang Pharmaceutical Co., Ltd., Chengdu Nuodikang Biopharmaceutical Co., Ltd., Tibet Nuodikang Tibetan Medicinal Materials Development Co., Ltd., Tibet Nuodikang Pharmaceutical Co., Ltd., Hong Kong Topregi Pharmaceutical Co., Ltd., Tibet Yangdao Big Health Life Science Co., Ltd., Shanghai Xinhuo Biotechnology Co., Ltd., Tibet Nuodikang Technology Development Co., Ltd., and Tibet Nuodikang Biomedical Sales Co., Ltd.

The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical pharmaceuticals; they involve fields such as cardiovascular and cerebrovascular diseases, liver and gallbladder diseases, orthopedic pain relief, rheumatism, and cold medications. The core products include "Xinhuosu", the first Class I new national biological product in China for the treatment of acute heart failure independently developed by the company, "Nuodikang" made from the Tibetan medicinal material Rhodiola rosea as the raw material, and "Imdur", a first-line drug for cardiovascular diseases internationally. In addition, the company also has excellent national traditional Chinese medicine varieties such as "Xueshan Jinluohan Pain-relieving Film Coating", "Shiwei Dida Capsules", and "Xiao'er Shuangqing Granules".